Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogens

8 Oct 2024

Abstract excerpt

Abstract We previously described a two-component protein nanoparticle vaccine platform that displays 60 copies of the SARS-CoV-2 spike protein RBD (RBD-NP). The vaccine, when adjuvanted with AS03, was shown to elicit robust neutralizing antibody and CD4 T cell responses in Phase I/II clinical trials, met its primary co-endpoints in a Phase III trial, and has been licensed by multiple regulatory authorities under...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing
Share to vaccines and immunoinformatics approaches

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39379400
DOI: 10.1038/s41541-024-00982-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Potent neutralization of SARS-CoV-2 variants by RBD nanoparticle and prefusion-stabilized spike immunogensPMID 39379400Read ↗

Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variantsSemantic proximity Read ↗

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccinesSemantic proximity Read ↗

Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2Semantic proximity Read ↗

Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 VariantsSemantic proximity Read ↗

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccinesSemantic proximity Read ↗

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responsesSemantic proximity Read ↗

Stabilization of the SARS-CoV-2 Spike receptor-binding domain using deep mutational scanning and structure-based designSemantic proximity Read ↗

Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design.Semantic proximity Read ↗

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2Semantic proximity Read ↗

Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drive rapid and potent immunogenicity capable of single-dose protectionSemantic proximity Read ↗

Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variantsSemantic proximity Read ↗

Incorporation of Sars-Cov-2 Spike Ntd to Rbd-Based Vaccine Improves Immunity and Protection Against Viral VariantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.